ciclosporin ophthalmic; cyclosporine A ophthalmic (Restasis, Cequa)
Jump to navigation
Jump to search
Introduction
Tradenames: Restasis, Cequa:FDA-approved Aug 2018
Indications
- severe keratitis in adults with xerophthalmia (NICE) [NGC]
Contraindications
- not for moderate dry eyes (xerophthalmia)[2]
Dosage
- apply BID Cequa: 0.09% cyclosporine A ophthalmic
Notes
- Restasis: $175/month (2003)[1]
More general terms
References
- ↑ 1.0 1.1 Prescriber's Letter 10(4):23 2003
- ↑ 2.0 2.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/